Clinically available NMDA antagonist, memantine, attenuates tolerance to analgesic effects of morphine in a mouse tail flick test

Polish Journal of Pharmacology

Volumn 51, Issue 3, 1999, Pages 223-231

  Popik, Piotr ^a   Kozela, Ewa ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Analgesia; Memantine; Morphine; NMDA antagonist; Tolerance

Indexed keywords

MEMANTINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; MALE; MORPHINE TOLERANCE; MOUSE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MEMANTINE; MICE; MORPHINE; PAIN MEASUREMENT; RECEPTORS, N-METHYL-D-ASPARTATE; TAIL; TIME FACTORS;

EID: 0033018004     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ambrozi L., Danielczyk W.: Treatment of impaired cerebral function in psychogeriatric patients with memantine - results of a phase II double-blind study. Pharmacopsychiatry, 1988, 21, 144-146.
2. Belozertseva I. V., Bespalov A. Y.: Effects of NMDA receptor channel blockers, dizocilpine and memantine, on the development of opiate analgesic tolerance induced by repeated morphine exposures or social defeats in mice. Naunyn-Schmied. Arch. Pharmacol., 1998, 358, 270-274.
3. Ben-Eliyahu S., Marek P., Vaccarino A. L., Mogil J. S., Sternberg W. F., Liebeskind J. C.: The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res., 1992, 575, 304-308.
4. Benveniste H., Drejer J., Schousboe A., Diemer N. H.: Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem, 1984, 43, 1369-1374.
5. Bilsky E. J., Inturrisi C. E., Sadee W., Hruby V. J., Porreca F.: Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. Pain, 1996, 68, 229-237.
6. Bisaga A., Krzaścik P., Jankowska E., Palejko W., Kostowski W., Danysz W.: Effect of glutamate receptor antagonist on N-methyl-D-aspartate and (S)-alpha-amino-3-hydroxy-5-methy-4-isoxazolepropionic acid-induced convulsant effects in mice and rats. Eur. J. Pharmacol., 1993, 242, 213-220.
7. Bormann J.: Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol., 1989, 166, 591-592.
8. Bresink I., Danysz W., Parsons C. G., Mutschler E.: Different binding affinities of NMDA receptor channel blockers in various brain regions - indication of NMDA receptor heterogeneity. Neuropharmacology, 1995, 34, 533-540.
9. Chen L., Huang L. Y.: Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by amu opioid. Neuron, 1991, 7, 319-326.
10. Chen H. S., Pellegrini J. W., Aggarwal S. K., Lei S. Z., Warach S., Jensen F. E., Lipton S.A.: Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci., 1992, 12, 4427-4436.
11. Clements J. D., Lester R. A., Tong G., Jahr C. E., Westbrook G. L.: The time course of glutamate in the synap tic cleft. Science, 1992, 258, 1498-1501.
12. Cochin J., Kornetsky C.: Development and loss of tolerance to morphine in the rat after single and multiple injections. J. Pharmacol. Exp. Ther., 1964, 145, 1-10.
13. Danysz W., Parsons C. G., Kornhuber J., Schmidt W. J., Quack G.: Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev., 1997, 21, 455-468.
14. Danysz W., Zajaczkowski W., Parsons C. G.: Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol., 1995, 6, 455-474.
15. Dewey W. L., Harris L. S.: The tail flick test. In: Methods in Narcotic Research. Eds. Ehrenpreis S., Neidle A., Marcel Dekker, New York, 1975, 101-109.
16. Ditzler K.: Efficacy and tolerability of memantine in patients with dementia syndrome. A double blind, placebo controlled trial. Arzneim.-Forsch.-Drug Res., 1991, 41, 773-780.
17. Elliott K., Minami N., Kolesnikov Y.A., Pasternak G. W., Inturrisi C. E.: The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, Ng-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain, 1994, 56, 69-75.
18. Foley K. M.: Clinical tolerance to opioids. In: Towards a New Pharmacotherapy of Pain. Eds. Basbaum A. I., Besson J. M., John Wiley, 1991, 181-204.
19. Gonzalez P., Cabello P., Germany A., Norris B., Contreras E.: Decrease of tolerance to, and physical dependence on morphine by glutamate receptor antagonists. Eur. J. Pharmacol., 1997, 332, 257-262.
20. Greenamyre J. T., O'Brien C. F.: N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol., 1991, 48, 977-981.
21. Greenamyre J. T., Young A. B.: Excitatory amino acids and Alzheimer's disease. Neurobiol. Aging, 1989, 10, 593-602.
22. Hagen N. A., Swanson R.: Multifocal myoclonus and seizures in extremely high-dose opioid administration. Neurology, 1993, 43, 9338.
23. Herman B. H., O'Brien C. P.: Clinical medications development for opiate addiction: focus on nonopioicls and opioid antagonists for the amelioration of opiate withdrawal symptoms and relapse prevention. Semin. Neurosci., 1997, 9, 158-172.
24. Herman B. H., Vocci F., Bridge P.: The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. Neuropsychopharmacology, 1995, 13, 269-293.
25. Kesner R. P., Priano D. J., DeWitt J. R.: Time-dependent distribution of morphine tolerance by electroconvulsive shock and frontal cortical stimulation. Science, 1976, 194, 1079-1081.
26. Kornhuber J., Bormann J., Hubers M., Rusche K., Riederer P.: Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol., 1991, 206, 297-300.
27. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol., 1989, 166, 589-590.
28. Leppik I. E., Marienau K., Graves N. M., Rask C. A.: MK-801 for epilepsy: a pilot study. Neurology, 1988, 38, 405.
29. Lutfy K., Hurlbut D. E., Weber E.: Blockade of morphine-induced analgesia and tolerance in mice by MK-801. Brain Res., 1993, 616, 83-88.
30. Lutfy K., Shen K. Z., Kwon I. S., Cai S. X., Woodward R. M., Keana J. F. W., Weber E.: Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor glycine site antagonist. Eur. J. Pharmacol., 1995, 273, 187-189.
31. Malec D., Langwiński R.: Central action of narcotic analgesics. VIII. The effect of dopaminergic stimulants on the action of analgesics in rats. Pol. J. Pharmacol. Pharm., 1981, 33, 273-282.
32. Mao J., Price D. D., Mayer D. J.: Mechanisms of hyper-algesia and morphine tolerance: a current view of their possible interactions. Pain, 1995, 62, 259-274.
33. Martin W. R., Jasinski D. R.: Physiological parameters of morphine dependence in man - tolerance, early abstinence, protracted abstinence. J. Psychiat. Res., 1969, 7, 9-17.
34. Meldrum B. S., Turski L., Schwarz M., Czuczwar S. J., Sontag K.-H.: Anticonvulsant action of 1,3-dimethyl-5-aminoadamantane. Pharmacological studies in rodents and baboon, Papio papio. Naunyn-Schmied. Arch. Pharmacol, 1986, 332, 93-97.
35. Moryl E., Danysz W, Quack G.: Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol., 1993, 72, 394-397.
36. Muir K. W., Grosset D. G., Gamzu E., Lees K. R.: Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Brit. J. Clin. Pharmacol., 1994, 38, 33-38.
37. Paronis C. A., Holtzman S. G.: Increased analgesic potency of mu agonists after continuous naloxone infusion in rats. J. Pharmacol. Exp. Ther., 1991, 259, 582-589.
38. Parsons C. G., Gruner R., Rozental J., Millar J., Lodge D.: Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology, 1993, 32, 1337-1350.
39. Parsons C. G., Panchenko V. A., Pinchenko V. O., Tsyndrenko A. Y., Krishtal O. A.: Comparative patchclamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur. J. Neurosci., 1996, 8, 446-454.
40. Parsons C. G., Quack G., Bresink I., Baran L., Przegaliński E., Kostowski W., Krzaścik P., Hartmann S., Danysz W.: Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology, 1995, 34, 1239-1258.
41. Popik P., Danysz W.: Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by NMDA receptor antagonist, memantine. J. Pharmacol. Exp. Ther., 1997, 280, 854-865.
42. Porter R. H., Greenamyre J. T.: Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem., 1995, 64, 614-623.
43. Rabey J. M., Nissipeanu P., Korczyn A. D.: Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J. Neural Transm.-Parkinsons, 1992, 4, 277-282.
44. Riederer P., Lange K.W., Kornhuber J., Danielczyk W.: Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet, 1991, 338, 1022-1023.
45. Seif el Nasr M., Peruche B., Rossberg C., Mennel H. D., Krieglstein J.: Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur. J. Pharmacol., 1990, 185, 19-24.
46. Siegel S.: Evidence from rats that morphine tolerance is a learned response. J. Comp. Physiol. Psychol., 1975, 89, 498-506.
47. Siegel S.: Morphine analgesic tolerance: its situation specificity supports a Pavlovian conditioning model. Science, 1976, 193, 323-325.
48. Sveinbjornsdottir S., Sander J. W., Upton D., Thompson P. J., Patsalos P. N., Hirt D., Emre M., Lowe D., Duncan J. S.: The excitatory amino acid antagonist DCPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res., 1993, 16, 165-174.
49. Trujillo K. A., Akil H.: Opiate tolerance and dependence: recent findings and synthesis. New Biol., 1991, 3, 915-923.
50. Welch S. P., Olson K. G.: Opiate tolerance-induced modulation of free intracellular calcium in synaptosomes. Life Sci., 1991, 48, 1853-1861.
51. Weller M., Finiels-Marlier F., Paul S. M.: NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res., 1993, 613, 143-148.
52. Wenk G. L., Danysz W., Mobley S. L.: MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol.-Environ. Toxic., 1995, 293, 267-270.
53. Wesemann W., Sturm G., Funfgeld E. W.: Distribution and metabolism of the potential anti-parkinson drug memantine in the human. J. Neural Transm., Suppl., 1980, 143-148.
54. World Health Organization: Cancer Pain Relief. WHO, Geneva, 1986.